» Articles » PMID: 23403721

Exploring Mechanisms of FGF Signalling Through the Lens of Structural Biology

Overview
Date 2013 Feb 14
PMID 23403721
Citations 282
Authors
Affiliations
Soon will be listed here.
Abstract

Fibroblast growth factors (FGFs) mediate a broad range of functions in both the developing and adult organism. The accumulated wealth of structural information on the FGF signalling pathway has begun to unveil the underlying molecular mechanisms that modulate this system to generate a myriad of distinct biological outputs in development, tissue homeostasis and metabolism. At the ligand and receptor level, these mechanisms include alternative splicing of the ligand (FGF8 subfamily) and the receptor (FGFR1-FGFR3), ligand homodimerization (FGF9 subfamily), site-specific proteolytic cleavage of the ligand (FGF23), and interaction of the ligand and the receptor with heparan sulphate cofactor and Klotho co-receptor.

Citing Articles

Inhibition Effects and Mechanism Study of rAj-HRP30, a Recombinant Histidine-Rich Peptide from , on the Viability of Pancreatic Ductal Adenocarcinoma Cells Panc01 and Panc02.

Song Y, Gao S, Jiang J, Zhang Y, Zhang J, Wang X Int J Mol Sci. 2025; 26(4).

PMID: 40003950 PMC: 11854995. DOI: 10.3390/ijms26041485.


Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3.

Snow A, Wijesiriwardena T, Lane B, Farrell B, Dowdle P, Katan M Sci Rep. 2025; 15(1):2958.

PMID: 39848978 PMC: 11758000. DOI: 10.1038/s41598-025-86194-6.


Hepatocyte-Derived FGF1 Alleviates Isoniazid and Rifampicin-Induced Liver Injury by Regulating HNF4α-Mediated Bile Acids Synthesis.

Lin Q, Zhang J, Qi J, Tong J, Chen S, Zhang S Adv Sci (Weinh). 2024; 12(7):e2408688.

PMID: 39731358 PMC: 11831436. DOI: 10.1002/advs.202408688.


Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.

Peng M, Deng J, Li X Mol Cancer. 2024; 23(1):256.

PMID: 39543657 PMC: 11566285. DOI: 10.1186/s12943-024-02167-9.


The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Giacomini A, Taranto S, Gazzaroli G, Faletti J, Capoferri D, Marcheselli R J Exp Clin Cancer Res. 2024; 43(1):294.

PMID: 39482742 PMC: 11529022. DOI: 10.1186/s13046-024-03217-2.


References
1.
Goetz R, Ohnishi M, Kir S, Kurosu H, Wang L, Pastor J . Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem. 2012; 287(34):29134-46. PMC: 3436551. DOI: 10.1074/jbc.M112.342980. View

2.
Zhang X, Ibrahimi O, Olsen S, Umemori H, Mohammadi M, Ornitz D . Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281(23):15694-700. PMC: 2080618. DOI: 10.1074/jbc.M601252200. View

3.
Makarenkova H, Hoffman M, Beenken A, Eliseenkova A, Meech R, Tsau C . Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci Signal. 2009; 2(88):ra55. PMC: 2884999. DOI: 10.1126/scisignal.2000304. View

4.
Avivi A, Yayon A, Givol D . A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett. 1993; 330(3):249-52. DOI: 10.1016/0014-5793(93)80882-u. View

5.
Yayon A, Zimmer Y, Shen G, Avivi A, Yarden Y, Givol D . A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J. 1992; 11(5):1885-90. PMC: 556646. DOI: 10.1002/j.1460-2075.1992.tb05240.x. View